Justin B Echouffo-Tcheugui1, Kinfe G Bishu2, Gregg C Fonarow3, Leonard E Egede4. 1. Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA. 2. Center for Health Disparities Research, Division of General Internal Medicine, Medical University of South Carolina, Charleston, SC; Department of Medicine, Division of General Internal Medicine and Geriatrics, Medical University of South Carolina, Charleston, SC. 3. Ahmanson-UCLA Cardiomyopathy Center, Ronald Reagan-UCLA Medical Center, Los Angeles, CA. 4. Division of General Internal Medicine, The Medical College of Wisconsin, Milwaukee, WI. Electronic address: legede@mcw.edu.
Abstract
Population-based national data on the trends in expenditures related to heart failure (HF) are scarce. Assessing the time trends in health care expenditures for HF in the United States can help to better define the burden of this condition. METHODS: Using 10-year data (2002-2011) from the national Medical Expenditure Panel Survey (weighted sample of 188,708,194US adults aged ≥18years) and a 2-part model (adjusting for demographics, comorbidities, and time); we estimated adjusted mean and incremental medical expenditures by HF status. The costs were direct total health care expenditures (out-of-pocket payments and payments by private insurance, Medicaid, Medicare, and other sources) from various sources (office-based visits, hospital outpatient, emergency department, inpatient hospital, pharmacy, home health care, and other medical expenditures). RESULTS: Compared with expenditures for individuals without HF ($5511 [95% CI 5405-5617]), individuals with HF had a 4-fold higher mean expenditures of ($23,854 [95% CI 21,733-25,975]). Individuals with HF had $3446 (95% CI 2592-4299) higher direct incremental expenditures compared with those without HF, after adjusting for demographics and comorbidities. Among those with HF, costs continuously increased by $5836 (28% relative increase), from $21,316 (95% CI 18,359-24,272) in 2002/2003 to $27,152 (95% CI 20,066-34,237) in 2010/2011, and inpatient costs ($11,318 over the whole period) were the single largest component of total medical expenditure. The estimated unadjusted total direct medical expenditures for US adults with HF were $30 billion/y and the adjusted total incremental expenditure was $5.8 billion/y. CONCLUSIONS: Heart failure is costly and over a recent 10-year period, and direct expenditure related to HF increased markedly, mainly driven by inpatient costs.
Population-based national data on the trends in expenditures related to heart failure (HF) are scarce. Assessing the time trends in health care expenditures for HF in the United States can help to better define the burden of this condition. METHODS: Using 10-year data (2002-2011) from the national Medical Expenditure Panel Survey (weighted sample of 188,708,194US adults aged ≥18years) and a 2-part model (adjusting for demographics, comorbidities, and time); we estimated adjusted mean and incremental medical expenditures by HF status. The costs were direct total health care expenditures (out-of-pocket payments and payments by private insurance, Medicaid, Medicare, and other sources) from various sources (office-based visits, hospital outpatient, emergency department, inpatient hospital, pharmacy, home health care, and other medical expenditures). RESULTS: Compared with expenditures for individuals without HF ($5511 [95% CI 5405-5617]), individuals with HF had a 4-fold higher mean expenditures of ($23,854 [95% CI 21,733-25,975]). Individuals with HF had $3446 (95% CI 2592-4299) higher direct incremental expenditures compared with those without HF, after adjusting for demographics and comorbidities. Among those with HF, costs continuously increased by $5836 (28% relative increase), from $21,316 (95% CI 18,359-24,272) in 2002/2003 to $27,152 (95% CI 20,066-34,237) in 2010/2011, and inpatient costs ($11,318 over the whole period) were the single largest component of total medical expenditure. The estimated unadjusted total direct medical expenditures for US adults with HF were $30 billion/y and the adjusted total incremental expenditure was $5.8 billion/y. CONCLUSIONS:Heart failure is costly and over a recent 10-year period, and direct expenditure related to HF increased markedly, mainly driven by inpatient costs.
Authors: Yuji Okura; Lynn H Urban; Douglas W Mahoney; Steven J Jacobsen; Richard J Rodeheffer Journal: J Clin Epidemiol Date: 2004-10 Impact factor: 6.437
Authors: Kathleen T Unroe; Melissa A Greiner; Adrian F Hernandez; David J Whellan; Padma Kaul; Kevin A Schulman; Eric D Peterson; Lesley H Curtis Journal: Arch Intern Med Date: 2010-10-11
Authors: Wei Ning Chi; Courtney Reamer; Robert Gordon; Nitasha Sarswat; Charu Gupta; Emily White VanGompel; Julie Dayiantis; Melissa Morton-Jost; Urmila Ravichandran; Karen Larimer; David Victorson; John Erwin; Lakshmi Halasyamani; Anthony Solomonides; Rema Padman; Nirav S Shah Journal: Appl Clin Inform Date: 2021-12-29 Impact factor: 2.342
Authors: Paul A Heidenreich; Gregg C Fonarow; Yekaterina Opsha; Alexander T Sandhu; Nancy K Sweitzer; Haider J Warraich Journal: J Card Fail Date: 2022-01-24 Impact factor: 6.592
Authors: Boback Ziaeian; Paul A Heidenreich; Haolin Xu; Adam D DeVore; Roland A Matsouaka; Adrian F Hernandez; Deepak L Bhatt; Clyde W Yancy; Gregg C Fonarow Journal: JACC Heart Fail Date: 2018-04-11 Impact factor: 12.035
Authors: Derek S Chew; Patricia A Cowper; Hussein Al-Khalidi; Kevin J Anstrom; Melanie R Daniels; Linda Davidson-Ray; Yanhong Li; Robert E Michler; Julio A Panza; Ileana L Piña; Jean L Rouleau; Eric J Velazquez; Daniel B Mark Journal: Circulation Date: 2022-01-19 Impact factor: 29.690